Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surfaxin for prevention of bronchopulmonary dysplasia in very low birth weight premature infants
2005-000015-10Phase 3Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Apr 2005
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchopulmonary dysplasia (BPD) comparing Surfaxin with Placebo (2 arms). Primary endpoints: Acute safety and tolerability, Complications of prematurity and 5 more. Started Apr 2005; status: completed.
02
Drugs
lucinactant
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2005-000015-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000015-10.